Catalogue preview · final packaging and presentation may vary if stockedFive choices across your ballotUse votes only for compounds you would consider ordering
One vote per compoundEach candidate can be selected once on this browser
Flexible interest signalRemove or reassign a vote whenever you like
PNC-27
PNC-27 is an experimental peptide built from a p53-derived sequence joined to a membrane-resident peptide. It has been studied for selective membrane-disrupting activity in cancer-cell and tumour-model research.
Loading your saved choices…
PNC-27 is currently being evaluated through customer voting and is not available to order. Final product specifications and batch documentation will be published only if it joins the catalogue.
This page records catalogue interest only. If PNC-27 is selected for supply, Puffin will publish the confirmed format, batch documentation, and laboratory preparation information on the product listing.
Storage and handling requirements depend on the final supplied format. Confirmed instructions will be provided with the batch details if this candidate is added to the catalogue.
Understanding PNC-27
Explore the science, research focus, and key information behind this compound.
What is PNC-27?+
PNC-27 is a specialist choice for controlled studies centred on membrane behaviour and selective cellular response.
What Researchers Study+
Researchers examine Membrane-interaction models, p53-derived peptide activity, and Selective cellular-response research.
How PNC-27 Works+
The proposed model is that the p53-derived region interacts with HDM-2 displayed on some cancer-cell membranes, bringing the membrane-active segment close enough to form pores. In plain language, the research asks whether a target on the cell surface can help direct a lytic peptide toward selected cells.
Research at a Glance+
Cancer-cell membrane lysis has been reported. Laboratory studies have described rapid membrane pore formation and tumour-cell killing in selected models. These are mechanism-generating findings, not clinical evidence of a safe or effective cancer therapy. Selectivity must be tested—not assumed. A membrane-active peptide can look potent in vitro. The key research challenge is whether target expression, delivery, and exposure create a useful window between selected and non-target cells. Delivery is a separate unsolved problem. A peptide can lyse exposed cells in a dish yet fail to reach a tumour selectively in an organism. Stability, distribution, immune response, and normal-tissue exposure all require direct study.
If this candidate is added to the catalogue, it would be offered for controlled laboratory research only. It is not for human consumption and is not represented as a medicine, treatment, supplement, or substitute for an approved product.